The information of our products contained in this section is partial and for orientation purposes only. A health care professional or certified physician must always be consulted for an appropriate diagnosis and use of these medications.
BRAND DRUG SUBSTANCE PRESENTATION
Induction: IV infusion: 5 mg per kg of body weight, administered during at least 1 hour, every 12 hours for 14 to 21 days. Intravitreal Injection: 200 mcg in 0.1 ml twice a week for 3 weeks. Maintenance: IV infusion: 5 mg per kg of body weight once a day, administered during at least 1 hour, once a day on week days, or 6 mg per kg of body weight, administered during at least 1 hour, once a day 5 days a week. Intravitreal Injection: 200 mcg in 0.1 ml once a week.
Dosing was not established for pediatric use.
For sale under filed prescription
Sofosbuvir is indicated for the treatment of infection by genotypes 1, 2, 3 or 4 of the chronic
Hepatitis C virus (HCV) as a component in the combined antiviral treatment regimen.
The recommended sofosbuvir dose is one 400 mg film-coated tablet, oral, once daily with or without food.
Sofosbuvir should be administered in combination with ribavirin or in combination with pegylated interferon and ribavirin for the treatment of HCV. The recommended treatment regimen and the duration of the sofosbuvir combination therapy are indicated in the following table.
Genotype 1 or 4
Sofosbuvir + peginterferon alfa + ribavirin
Sofosbuvir + ribavirin
Sofosbuvir + ribavirin
Each tablet of Trivenz contains: 600 mg Efavirenz , 200 mg Emtricitabine, 300 mgTenofovir DF.
A combination of antiretrovirals to treat HIV infection.
Code ATC: J05AR06.
Trivenz is indicated alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults or pediatric patients of 12 years of age or older.
The recommended dose of Trivenz is one tablet taken orally once daily with an empty stomach. Bedtime administration may improve the tolerability of nervous system symptoms.
Kidney insufficiency: Due to Trivenz is a fixed-dose combination, it should not be prescribed for patients requiring dose adjustments such as those with moderate or severe renal insufficiency (Creatinine clearance less than 50mL / min). Coadministration with Rifampin: When Trivenz is administered with rifampin to patients with a weight of 50 kg or more, an additional dose of 200 mg / day efavirenz is recommended.
Package containing 30 coated tablets.
Virontar N co-administered with other antiretroviral agents, is indicated for the treatment of infection by the human immunodeficiency virus (HIV-1 in: Adult patients without previous antiretroviral treatment (naïve). Adult patients with previous antiretroviral treatment without mutations associated with resistance to darunavir. In previously untreated adult patients should be considered the following points when starting Virontar N therapy: Treatment history and, when available, genotypic or phenotypic tests should guide the use of Virontar N. The use of other active agents with Virontar N is associated with an increased possibility of response to treatment. -->
The recommended dose is a coated tablet of Virontar N (darunavir 800 mg / ritonavir 100 mg) once daily administered with food.
EIn patients previously treated with antiretroviral treatment without mutations associated with resistance to darunavir (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V and L89V)can be used a coated tablet of Virontar N administered once a day with food. For patients with prior antiretroviral therapy is recommended genotypic testing.
No dose adjustment is required in patients with mild or moderate hepatic impairment. No information available on the use of Virontar N when co-administered to patients with severe hepatic impairment, therefore the use of Virontar N is not recommended in patients with severe hepatic impairment.
600 mg administered orally once a day. Concomitant antiretroviral treatment: Efavirenz must be administered in combination with other antiretroviral medications.
Body weight of 13-15 kg: 200 mg. Body weight of 15-20 kg: 250 mg. Body weight of 20-25 kg: 300 mg. Body weight of 25-32.5 kg: 350 mg. Body weight of 32.5-40 kg: 400 mg. The recommended dose for children whose body weight is over 40 kg is 600 mg, once a day.
Adults and children older than 12 years of age: 300 mg twice a day. Children from 3 Months to 16 Years of Age: 8 mg/kg twice a day up to a maximum of 600 mg per day. Abacavir may be taken with or without food.
Adults and children older than 12 years of age: The recommended dose of lamivudine/zidovudine is 1 tablet twice a day..
With symptomatic infection, 100 mg (10 ml of syrup) every 4 hours (total daily dose 600 mg). With asymptomatic infection, 100 mg. every 4 hours, while the patient is asleep (total daily dose 600 mg.).
from 3 months to 12 years of age, 180 mg/m2 of body surface area, every 6 hours.
Note: Products which are still under patent are manufactured according to Argentinean requirements. Please note that they are delivered only to countries where the substance and its use are not protected by patents.